Concepedia

Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.

James R. Tonra, Erik Corcoran, Dhanvanthri S. Deevi, Philipp Steiner, Jessica Kearney, Huiling Li, Dale L. Ludwig, Zhenping Zhu, Larry Witte, David Surguladze,

PubMed · 2009 · 14 citations · 23 references

Abstract

Targeting VEGFR2 + EGFR was prioritized over other treatment strategies utilizing EGFR, IGF-IR and VEGFR2 antibodies. The criteria that proved to be valuable were a non-overlapping spectrum of anticancer activity and the prevention of resistance to another therapy in the combination.

References

23

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis

B Millauer, Susanne Wizigmann-Voos, Harald Schnürch et al. · Cell · 1993 · 1.9K citations

, , +9

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Oriol Casanovas, Daniel J. Hicklin, Gabriele Bergers et al. · Cancer Cell · 2005 · 1.6K citations · Full text

, , +9

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

Constantine S. Mitsiades, Nicholas Mitsiades, Ciaran J. McMullan et al. · Cancer Cell · 2004 · 610 citations

, , +9

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

Alicia Viloria‐Petit, Tania Crombet, S Jothy et al. · PubMed · 2001 · 557 citations

, , +17

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

Roy S. Herbst, David H. Johnson, Eric D. Mininberg et al. · Journal of Clinical Oncology · 2005 · 535 citations · Full text